KEYNOTE-826: New standard of care in cervical cancer

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 18 / Springer Healthcare

KEYNOTE-826: New standard of care in cervical cancer

Oncology Cervical Cancer ESMO-2021

Description

Mansoor Raza Mirza provides his comments on study results supporting a new standard of care with pembrolizumab plus chemotherapy in women with persistent, recurrent or metastatic cervical cancer.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.